Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy

**Background:** Two thirds (62%) of metastatic breast cancer (MBC) patients in Western Europe have human epidermal growth factor receptor 2 (HER2)-negative disease, for which anthracyclines and taxanes are recommended as first-line treatments, followed by microtubule-targeting agents such as capecit...

Full description

Bibliographic Details
Main Authors: Gabriel Tremblay, Unnati Majethia, Ilias Kontoudis, Jesús De Rosendo
Format: Article
Language:English
Published: Columbia Data Analytics, LLC
Series:Journal of Health Economics and Outcomes Research
Online Access:http://jheor.scholasticahq.com/article/9834-cost-effectiveness-analysis-of-eribulin-mesylate-as-a-treatment-for-metastatic-breast-cancer-in-spain-management-in-the-later-line-of-therapy.pdf

Internet

http://jheor.scholasticahq.com/article/9834-cost-effectiveness-analysis-of-eribulin-mesylate-as-a-treatment-for-metastatic-breast-cancer-in-spain-management-in-the-later-line-of-therapy.pdf

Similar Items